Once-Weekly Insulin: FDA Approves Awiqli for Type 2 Diabetes

Daily subcutaneous injections of basal insulin present a significant physical and emotional burden for many adults with type 2 diabetes, often leading to missed doses, inconsistent glycemic control, and reduced quality of life. The approval by the U.S. Food and Drug Administration (FDA) of the first once-weekly basal insulin under the brand name Awiqli (insulin icodec) offers an opportunity to reduce mandatory injections from 365 to 52 per year. This milestone marks a transition to a new phase in insulin therapy designed to improve convenience and provide stable medication concentration in the body.

Molecular Mechanism and Duration of Action

Awiqli is an innovative ultra-long-acting human insulin analog developed to provide stable basal insulin coverage over seven days. Following subcutaneous injection, insulin icodec molecules rapidly and reversibly bind to albumin, the primary protein in blood serum. This forms a circulating depot of the drug within blood plasma and interstitial fluid. From this depot, active insulin is released slowly and continuously, preventing sharp concentration peaks and providing an even blood glucose-lowering effect.

The elimination half-life of insulin icodec is approximately 196 hours (nearly 8 days), significantly exceeding that of existing daily basal insulins. Thanks to this pharmacokinetic profile, steady-state plasma concentrations are typically achieved after 2 to 4 weeks of regular weekly administration. At the cellular level, the mechanism of action involves binding to insulin receptors, promoting glucose transport into muscle and adipose tissues, inhibiting hepatic glucose production, and suppressing lipolysis.

Clinical Evidence: Results from the ONWARDS Program

Decisions by international regulatory bodies, including the FDA and the European Medicines Agency (EMA), rely on data from the extensive phase 3a clinical trial program named ONWARDS. In these randomized, active-controlled trials involving over 4,000 adults with type 2 diabetes, the efficacy and safety of Awiqli were compared against daily basal insulins, such as insulin glargine U100 and insulin degludec.

In the ONWARDS 1 trial involving insulin-naive adults with type 2 diabetes, once-weekly insulin icodec demonstrated a mean HbA1c reduction of 1.55% compared to 1.35% with once-daily insulin glargine U100. Continuous glucose monitoring data showed that time in target range (70–180 mg/dL) reached 71.9% for participants on Awiqli, compared to 66.9% for those on once-daily comparator insulin. However, regulatory approval is strictly limited to adults with type 2 diabetes, as trials in individuals with type 1 diabetes indicated an increased risk of hypoglycemic events.

Practical Aspects of Administration and Safety

Awiqli is supplied in a prefilled pen at a concentration of 700 units/mL and is administered subcutaneously into the abdomen, thigh, or upper arm once weekly. Injections should be given on the same day each week to establish a consistent schedule. If necessary, the day of weekly administration can be adjusted, provided that the interval between two consecutive injections is at least three days.

Switching from daily basal insulin to once-weekly insulin is calculated using specific dosing algorithms under mandatory clinical supervision. As with any insulin therapy, the primary safety considerations include the risk of hypoglycemia and individual hypersensitivity. Patients are advised to monitor blood glucose levels regularly, particularly during dose titration and the initial months of treatment, and to keep fast-acting carbohydrates readily accessible.

Practical Conclusion: What This Means for Patients

The approval of once-weekly basal insulin Awiqli represents a major advancement in diabetology that can simplify the daily routine for individuals with type 2 diabetes. Reducing the frequency of subcutaneous injections sevenfold enhances treatment adherence and supports more stable glycemic control.

If you have considered reducing injection frequency or experience challenges maintaining regular daily insulin dosing, discuss the potential appropriateness of once-weekly insulin with your healthcare provider. Any change in treatment regimen, choice of insulin, or initial dose calculation should be conducted under medical guidance based on individual glycemic targets.